Pancreatic cancer drug trial halted after safety issues

NCT ID NCT05525286

Terminated Disease control Sponsor: SOTIO Biotech a.s. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it helped shrink tumors. The study was stopped early because of unexpected safety problems that reappeared even after changes were made.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm Neoplasm Metastasis pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Cleveland Clinic Main Campus

Cleveland, Ohio, 44195, United States
Hospital Universitario HM Sanchinarro

Madrid, Spain
Institut Gustave Roussy

Paris, France
Institut Jules Bordet

Brussels, Belgium
Masarykův Onkologický Ústav

Brno, Czechia
Universitair Ziekenhuis Leuven - Campus Gasthuisberg

Leuven, Belgium
VHIO - Vall d'Hebron Institut d'Oncologia

Barcelona, Spain
Washington University School of Medicine in St. Louis

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.